Drive Your Discovery & Pre-Clinical Pipelines Into Robust Clinical Candidates by Improving Immune Response, Clinical Efficacy & Cost of Cancer Vaccines & Targeted Therapies
Welcome to the 8th International Neoantigen Summit:
Advancing Cancer Treatment with Durable, Effective Neoantigen Vaccines & Therapies
2024 saw a wealth of clinical progression with Nouscom, CureVac, Transgene and other pioneering companies, paving the way for neoantigen based vaccines and therapies to become tolerable, durable medicines to effectively treat cancer.
Ready to unite the global neoantigen community, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients.
Join neoantigen leaders from the likes of AstraZeneca, Geneos Therapeutics, Evaxion Biotech and many more at this end-to-end meeting, focusing on the development of durable, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe, efficacious personalized or off-the-shelf therapeutic options to patients, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success.
Brand New Agenda
What’s New for 2025?
New and improved in 2025, hear first-hand from world-class biopharma experts as they share data-driven insights on...
The latest clinical learnings to address bottlenecks in durability, dosing and toxicity helping to develop more effective neoantigen based therapies and vaccines
Rational neoantigen based combination strategies and clinical trial design considerations to unleash the full therapeutic potential of this class of drugs across oncology indications
Strategies to enhance time and cost-effectiveness of producing neoantigen vaccines and therapies for streamlined translation into the clinic
2025 Expert Speakers Include:
Don't Just Take Our Word For It...
“This is a pivotal forum for advancing the next generation of neoantigen-based cancer therapies and is an invaluable opportunity to engage with leading researchers, biotech innovators, and industry partners”
Chief Executive Officer, AilseBio
“The value of participating in the meeting is the opportunity for open exchange of scientific concepts and ideas, and meeting industry and academic colleagues who all share the same goal, to improve life and health of cancer patients”
Senior Director, CureVac
2025 Confirmed Partners:
